Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovidâs most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). Source
No articles found.
At Sesen Bio, we are committed to renewing life for people with cancer. We are a l...
At Sesen Bio, we are committed to renewing life...
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental...
Pluristem Therapeutics Inc. is a clinical-stage...
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
Alkermes plc is a fully integrated, global biopharmaceutical company developing in...
Alkermes plc is a fully integrated, global biop...
Join the National Investor Network and get the latest information with your interests in mind.